1. Camilleri M, Williams DE. Economic burden of irritable bowel syndrome. Proposed strategies to control expenditures. Pharmacoeconomics 2000;17(4):331–336.
2. Talley NJ, Gabriel SE, Harmsen WS, Zinsmeister AR, Evans RW. Medical costs in community subjects with irritable bowel syndrome. Gastroenterology 1995;109:1736–1741.
5. Drossman DA, Li Z, Andruzzi E, Temple RD, Talley NJ, Thompson WG, Whitehead WE, Janssens J, Funch-Jensen P, Corazziari E, Richter JE, Koch GG. U.S. householder survey of functional gastrointestinal disorders. Dig Dis Sci 1993;38:1569–1580.
6. Sandler RS. Epidemiology of irritable bowel syndrome in the United States. Gastroenterology 1990;99:409–415.
7. Ragnarsson G, Bodemar G. Division of irritable bowel syndrome into subgroups on the basis of daily recorded systems in two outpatients’ samples. Scand J Gastroenterol 1999;34:993–1000.
8. Ragnarsson G, Bodemar G. Pain is temporally related to eating but not to defecation in the irritable bowel syndrome (IBS). Patients’ description of diarrhea, constipation and symptom variation during a prospective 6-week study. Eur J Gastroenterol Hepatol 1998;10:415–421.
9. Talley NJ, Zinsmeister AR, Van Dyke C, Melton J III. Epidemiology of colonic symptoms and the irritable bowel syndrome. Gastroenterology 1991;101:927–934.
12. Evans PR, Bennett EJ, Bak YT, Tennant CC, Kellow JE. Jejunal sensorimotor dysfunction in irritable bowel syndrome: clinical and psychosocial features. Gastroenterology 1996;110:393–404.
13. Vassallo MJ, Camilleri M, Phillips SF, Steadman CJ, Hanson RB, Haddad AC. Colonic tone and motility in patients with irritable bowel syndrome. May Clin Proc 1992;67:725–731.
14. Vassallo M, Camilleri M, Phillips SF, Brown ML, Chapman NJ, Thomforde GM. Transit through the proximal colon influences stool weight in the irritable bowel syndrome. Gastroenterology 1992;102:102–108.
15. Camilleri M, Northcutt AR, Kong S, Dukes GE, McSorley D, Mangel AW. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 2000;355:1035–1040.
16. Kellow JE, Phillips SF. Altered small bowel motility in irritable bowel syndrome is correlated with symptoms. Gastroenterology 1987;92:1885–1893.
17. Serra J, Azpiroz F, Malagelada J-R. Intestinal gas dynamics and tolerance in humans. Gastroenterology 1998;115:542–550.
19. Mertz H, Naliboff B, Munakata J, Niazi N, Mayer EA. Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology 1995;109:40–52.
20. Kellow JE, Eckersley CM, Jones MP. Enhanced perception of physiological intestinal motility in the irritable bowel syndrome. Gastroenterology 1991;101:1621–7.
21. Schmulson M, Chang L, Naliboff B, Lee OY, Mayer EA. Correlation of symptom criteria with perception thresholds during rectosigmoid distension in irritable bowel syndrome patients. Am J Gastroenterol 2000;95:152–156.
23. Evans PR, Kellow JE. Physiological modulation of jejunal sensitivity in health and in irritable bowel syndrome. Am J Gastroenterol 1998;93:2191–6.
24. Evans PR, Piesse C, Bak YT, Kellow JE. Fructosesorbitol malabsorption and symptom provocation in irritable bowel syndrome: relationship to enteric hypersensitivity and dysmotility. Scand J Gastroenterol 1998;33:1158–63.
25. Silverman DH, Munakata JA, Ennes H, Mandelkern MA, Hoh CK, Mayer EA. Regional cerebral activity in normal and pathological perception of visceral pain. Gastroenterology 1997;112:64–72.
27. Santos J, Benjamin M, Yang P-C, et al. Chronic stress impairs rat growth and jejunal epithelial barrier function: role of mast cells. Am J Physiol 2000;278(6):G847–G854.
28. Aggarwal A, Cutts TF, Abell TL, Cardoso S, Familoni B, Bremer J, Karas J. Predominant symptoms in irritable bowel correlate with specific autonomic nervous system abnormalities. Gastroenterology 1994;106:945–950.
31. O’Sullivan M, Clayton N, Breslin NP, Harman I, Bountra C, McLaren A, O’Morain CA. Increased mast cells in the irritable bowel syndrome. Neurogastroenterol Mot 2000;12:449–457.
33. Luscombe FA. Health-related quality of life and associated psychosocial factors in the irritable bowel syndrome: a review. Qual Life Res 2000;9(2):161–176.
34. Camilleri M. Review article: clinical evidence to support current therapies of irritable bowel syndrome. Aliment Pharmacol Ther 1999;13(Suppl 2):48–53.
35. Camilleri M. Therapeutic approach to the patient with irritable bowel syndrome. Am J Med 1999;107(5A):27S–32S.
36. Licht HM. Irritable bowel syndrome: definitive diagnosis criteria help focus symptomatic treatment. Postgrad Med 2000;107:203–207.
37. Goldstein R, Braverman D, Stankiewicz H. Carbohydrate malabsorption and the effect of dietary restrictions on symptoms of irritable bowel syndrome and functional bowel complaints. Isr Med Assoc J 2000;2(8):583–587.
38. Talley NJ, Owen BK, Boyce P, Paterson K. Psychological treatments for irritable bowel syndrome: a critique of controlled clinical trials. Am J Gastroenterol 1996;91:277–286.
39. Heymann-Monnikes I, Arnold R, Florin I, Herda C, Melfsen S, Monnikes H. The combination of medical treatment plus multicomponent behavioral therapy is superior to medical treatment atone in the therapy of irritable bowel syndrome. Am J Gastroenterol 2000;95(4):981–994.
40. Klein KB. Controlled treatment trials in the irritable bowel syndrome. Gastroenterol 1988;95:232–241.
41. Jailwala J, Imperale TF, Kroenke K. Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann Intern Med 2000;133:136–147.
42. Clouse RE, Lustman PJ, Geisman RA, Alpers DH. Antidepressant therapy in 138 patients with irritable bowel syndrome: a five-year clinical experience. Aliment Pharmacol Ther 1994;8:409–416.
43. Sanger GJ. 5-hydroxytryptamine and functional bowel disorders. Neurogastroenterol Mot 1996;8:319–331.
44. Camilleri M. New pharmacological agent review: Tegaserod (Zelmac). Aliment Pharmacol Ther 2001;15(3):277–290.
45. Junien JL, Riviere P. The hypersensitive gut peripheral kappa agonists as a new pharmacological approach. Aliment Pharmacol Ther 1995;9:117–126.